Galapagos NV, a biotechnology company listed on Euronext and NASDAQ, announced the creation of a new subscription right plan aimed at compensating its senior management. On August 7, 2025, the company's Board of Directors approved "Subscription Right Plan 2025 $(B)$," which involves the creation of 1,800,000 subscription rights. These rights, subject to acceptance, allow senior management to subscribe to new Galapagos shares at an exercise price of €28.16 per share. The rights have an eight-year exercise term but cannot be exercised until the third anniversary of issuance. This plan is intended to align the interests of senior management with those of the shareholders by offering them a stake in the company's growth.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。